Over reveals baseball tickets the next conclude two years, the company expects to open five new beveragemanufacturing plants -- in Kunming, Zhengzhou, Quanzhou, Lanzhou and Nanchang. PepsiCo Opens First Overseas 'Green' Plant in China as Part of $1 BillionInvestment EffortCHONGQING, China, June 26 /PRNewswire-FirstCall/ -- PepsiCo (NYSE: PEP), oneof the world's largest food and beverage companies, opened its first overseas"green" plant in China today in the western city of Chongqing as it reiteratedplans to invest $1 billion in the country.The state-of-the-art beveragefacility is important to the company's ongoing strategy to expand in emergingmarkets and broaden its portfolio of locally relevant products.PepsiCo plans to fund a variety of major capital programs to grow itsmanufacturing capacity in China, particularly in interior and western areas. SOURCEGenomic Health, Inc.Investors, Brad Cole, +1-650-569-2281, , or Media,Emily Faucette, +1-650-569-2824, , both Genomic Health,Inc.. Genomic Health disclaims anyobligation to update these forward-looking statements. These forward-lookingstatements speak only as of the date hereof.
These risks and uncertainties include, but are not limitedto: the risk that Oncotype DX may not receive adequate reimbursement coveragein Europe, risks associated with international operations, the risks andpotential delays associated with commercialization of a new test; the risksand uncertainties associated with the regulation of the company's tests; theapplicability of clinical study results to actual outcomes; and the otherrisks set forth in the company's filings with the Securities and ExchangeCommission, including the risks set forth in the company's Quarterly Report onForm 10-Q for the quarter ended March 31, 2009 cubs rooftop . Forward-looking statements aresubject to risks and uncertainties that could cause actual results to differmaterially, and reported results should not be considered as an indication offuture performance . Gallen guidelines supports theexpansion of Oncotype DX in Europe, that inclusion of these types of tests insuch guidelines may also help establish favorable reimbursement policies inEurope, and the company's plans to commercialize a test for colon cancer andthe proposed timing of such commercialization . For moreinformation, please visit press release contains forward-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995, including statementsrelating to the company's belief that inclusion of the use of validatedmultigene assays such Oncotype DX in the St . The company wasfounded in 2000 and is located in Redwood City, California. In addition to thewidely adopted Oncotype DX breast cancer test, Genomic Health is preparing tolaunch its Oncotype DX colon cancer test in early 2010. In 2004, Genomic Health launched the Oncotype DX breastcancer test, which has been shown to predict the likelihood of chemotherapybenefit as well as recurrence in early-stage breast cancer.
(Nasdaq: GHDX) is a life science company focused on thedevelopment and commercialization of genomic-based clinical laboratoryservices for cancer that allow physicians and patients to make individualizedtreatment decisions kansas city royals . For more information about Oncotype DX, please visit Genomic Health Genomic Health, Inc . Both theAmerican Society of Clinical Oncology and the National Comprehensive CancerNetwork recommend the use of Oncotype DX for patients with node-negativebreast cancer that is estrogen-receptor positive and/or progesterone-receptorpositive . insured lives provide reimbursement forOncotype DX through contracts, agreements or policy decisions . To date, more than 8,000physicians have ordered more than 100,000 tests in over 40 countries.UnitedStates government health plans, such as Medicare, and private insurancecovering more than 90 percent of U.S.
Comments are closed.